Harnessing the power of foot-and-mouth-disease virus for targeting integrin alpha-v beta-6 for the therapy of cancer

References

• Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987;48(4):549–554.
   Web of Science ®Google Scholar
• Breuss JM, Gallo J, DeLisser HM, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995 Jun;108(Pt 6):2241–2251.
   PubMed Web of Science ®Google Scholar
• Saini G, Porte J, Weinreb PH, et al. αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur Respir J. 2015;46(2):486–494.
   PubMed Web of Science ®Google Scholar
• Niu J, Li Z. The roles of integrin alphavbeta6 in cancer. Cancer Lett. 2017 Sep 10;403:128–137.
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002 Sep 20;110(6):673–687.
   PubMed Web of Science ®Google Scholar
• Saha A, Ellison D, Thomas GJ, et al. High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J Pathol. 2010 Sep;222(1):52–63.
   PubMed Web of Science ®Google Scholar
• Acharya R, Fry E, Stuart D, et al. The three-dimensional structure of foot-and-mouth disease virus at 2.9 a resolution. Nature. 1989;337(6209):709–716.
   PubMed Web of Science ®Google Scholar
• Logan D, Abu-Ghazaleh R, Blakemore W, et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature. 1993;362(6420):566–568.
   PubMed Web of Science ®Google Scholar
• Fox G, Parry NR, Barnett PV, et al. The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol. 1989;70(Pt 3):625–637.
   Google Scholar
• Liebermann H, Dölling R, Schmidt D, et al. RGD-containing peptides of VP1 of foot-and-mouth disease virus (FMDV) prevent virus infection in vitro. Acta Virol. 1991;35(1):90–93.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12(1):697–715.
   PubMedGoogle Scholar
• Berinstein A, Roivainen M, Hovi T, et al. Antibodies to the vitronectin receptor (integrin alpha v beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol. 1995;69(4):2664–2666.
   PubMed Web of Science ®Google Scholar
• Kraft S, Diefenbach B, Mehta R, et al. Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem. 1999;274(4):1979–1985.
   Web of Science ®Google Scholar
• Mateu MG, Valero ML, Andreu D, et al. Systematic replacement of amino acid residues within an arg-gly-asp-containing loop of foot-and-mouth disease virus and effect on cell recognition. J Biol Chem. 1996;271(22):12814–12819.
   PubMed Web of Science ®Google Scholar
• Jackson T, Sheppard D, Denyer M, et al. The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. J Virol. 2000 Jun;74(11):4949–4956.
   PubMed Web of Science ®Google Scholar
• Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem. 1987;262(36):17294–17298.
   Web of Science ®Google Scholar
• Majken D, Richardson J, Vukelić B, et al. The disulfide bond of an RGD4C motif inserted within the Hi loop of the adenovirus type 5 fiber protein is critical for retargeting to αv -integrins. J Gene Med. 2012;14(12):788-797.
   Web of Science ®Google Scholar
• DiCara D, Rapisarda C, Sutcliffe JL, et al. Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem. 2007 Mar 30;282(13):9657–9665.
   PubMed Web of Science ®Google Scholar
• Hausner SH, Abbey CK, Bold RJ, et al. Targeted in vivo imaging of integrin αvβ6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res. 2009 Jul 15;69(14):5843–5850.
   PubMed Web of Science ®Google Scholar
• Hausner SH, Bauer N, Hu LY, et al. The effect of bi-terminal PEGylation of an integrin αvβ6–targeted 18f peptide on pharmacokinetics and tumor uptake. J Nucl Med. 2015 May;56(5):784–790.
   PubMed Web of Science ®Google Scholar
• Hausner SH, Bold RJ, Cheuy LY, et al. Preclinical development and first-in-human imaging of the integrin αvβ6 with [18F]αvβ6-binding peptide in metastatic carcinoma. Clin Cancer Res. 2019 Feb 15;25(4):1206–1215.
   PubMed Web of Science ®Google Scholar
• Lukey PT, Coello C, Gunn R, et al. Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL study). Eur J Nucl Med Mol Imaging. 2020;47(4):967–979.
   PubMed Web of Science ®Google Scholar
• Maher TM, Simpson JK, Porter JC, et al. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Respir Res. 2020;21(1). 10.1186/s12931-020-01339-7.
   Web of Science ®Google Scholar
• Saleem A, Helo Y, Win Z, et al. Integrin αvβ6 positron emission tomography imaging in lung cancer patients treated with pulmonary radiation therapy. Int J Radiat Oncol Biol Phys. 2020;107(2):370–376.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
   PubMed Web of Science ®Google Scholar
• Parente-Pereira AC, Shmeeda H, Whilding LM, et al. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid. J Iimmunol. 2014;193(11):5557–5566.
   PubMed Web of Science ®Google Scholar
• Hodgins NO, Al-Jamal WT, Wang JTW, et al. Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy. J Control Release. 2017;256:141–152.
   PubMed Web of Science ®Google Scholar
• Thomas JK, Kim MS, Balakrishnan L, et al. Pancreatic cancer database: an integrative resource for pancreatic cancer. Cancer Biol Ther. 2014;15(8). 10.4161/cbt.29188.
   PubMed Web of Science ®Google Scholar
• UK CR. Pancreatic cancer mortality statistics; 2015. [cited 2020 Sep]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/mortality
   Google Scholar
• Reader CS, Vallath S, Steele CW, et al. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J Pathol. 2019;249(3):332–342.
   PubMed Web of Science ®Google Scholar
• Steiger K, Schlitter AM, Weichert W, et al. Perspective of α v β6-integrin imaging for clinical management of pancreatic carcinoma and its precursor lesions. Mol Imaging. 2017;16:153601211770938.
   PubMed Web of Science ®Google Scholar
• Moore KM, Desai A, Delgado Bde L, et al. Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Theranostics. 2020;10(7):2930–2942.
   PubMed Web of Science ®Google Scholar
• Hausner SH, Kukis DL, Gagnon MKJ, et al. Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an αvβ6-specific peptide. Mol Imaging. 2009 Mar-Apr;8(2):111–121.
   PubMed Web of Science ®Google Scholar
• Hung KY, Harris PWR, Desai A, et al. Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N- and/or C-terminal functionality. Eur J Med Chem. 2017;136:154–164.
   PubMed Web of Science ®Google Scholar
• Hausner SH, Carpenter RD, Bauer N, et al. Evaluation of an integrin αvβ6-specific peptide labeled with [18F]fluorine by copper-free, strain-promoted click chemistry. Nucl Med Biol. 2013;40(2):233–239.
   PubMed Web of Science ®Google Scholar
• Baker AT, Aguirre-Hernández C, Halldén G, et al. Designer oncolytic adenovirus: coming of age. Cancers (Basel). 2018;10(6):201.
   Web of Science ®Google Scholar
• Roelvink PW, MiLee G, Einfeld DA, et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science (New York, NY). 1999;286(5444):1568–1571.
   Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science (New York, NY). 2015;347(6220):1260419.
   Google Scholar
• Wickham TJ, Filardo EJ, Cheresh DA, et al. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol. 1994;127(1):257–264.
   PubMed Web of Science ®Google Scholar
• Carlisle R, Di Y, Cerny A, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113(9):1909–1918.
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Gaggar A, Ni S, et al. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol. 2005;79(12):7478–7491.
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72(12):9706–9713.
   Web of Science ®Google Scholar
• Kurachi S, Tashiro K, Sakurai F, et al. Fiber-modified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity. Gene Ther. 2007;14(15):1160–1165.
   Web of Science ®Google Scholar
• Coughlan L, Vallath S, Saha A, et al. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol. 2009 Jul;83(13):6416–6428.
   PubMed Web of Science ®Google Scholar
• Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target αvβ6 and detarget the coxsackievirus–adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23(9):960–979.
   PubMed Web of Science ®Google Scholar
• Coughlan L, Uusi-Kerttula H, Ma J, et al. Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Hum Gene Ther. 2014;25(4):385–394.
   PubMed Web of Science ®Google Scholar
• Uusi-Kerttula H, Coughlan JD, Coughlan L. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget. 2016;7(19):27926–27937.
   PubMedGoogle Scholar
• Oberg D, Yanover E, Adam V, et al. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res off J Am Assoc Cancer Res. 2010;16(2):541–553.
   Google Scholar
• Man YKS, Davies JA, Coughlan L, et al. The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Mol Cancer Ther. 2018;17(2):575–587.
   Web of Science ®Google Scholar
• Stella MYK, Foster J, Carapuça E, et al. Systemic delivery and SPECT/CT in vivo imaging of 125 I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Sci Rep. 2019;9(1):1-12.
   Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–2554.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Whilding LM, Parente-Pereira AC, Zabinski T, et al. Targeting of aberrant αvβ6 integrin expression in solid tumors using chimeric antigen receptor-engineered T cells. Mol Ther. 2017;25(1):259–273.
   PubMed Web of Science ®Google Scholar
• Whilding LM, Halim L, Draper B, et al. CAR T-cells targeting the integrin αvβ6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel). 2019;11(5):674.
   PubMed Web of Science ®Google Scholar
• Boehm MK, Corper AL, Wan T, et al. Crystal structure of the anti-(carcinoembryonic antigen) single-chain fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J. 2000;346(2):519-528.
   PubMed Web of Science ®Google Scholar
• Chester KA, Mayer A, Bhatia J, et al. Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol. 2000;46(Suppl):S8-S12.
   PubMedGoogle Scholar
• Kogelberg H, Tolner B, Thomas GJ, et al. Engineering a single chain fv antibody to αvβ6 integrin using the specificity-determining loop of a foot-and-mouth disease virus. J Mol Biol. 2008 Oct 3;382(2):385–401.
   PubMed Web of Science ®Google Scholar
• Man YKS, DiCara D, Chan N, et al. Structural guided scaffold phage display libraries as a source of bio-therapeutics. PLoS One. 2013;8(8):e70452.
   Web of Science ®Google Scholar
• Kapp TG, Rechenmacher F, Neubauer S, et al. A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins. Sci Rep. 2017;7(1). 10.1038/srep39805.
   PubMedGoogle Scholar
• Hausner SH, DiCara D, Marik J, et al. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res. 2007 Aug 15;67(16):7833–7840.
   PubMed Web of Science ®Google Scholar
• Élez E, Kocáková I, Höhler T, et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015;26(1):132–140.
   Web of Science ®Google Scholar
• Imai KTA, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714–727.
   PubMed Web of Science ®Google Scholar
• Lavanya V, Adil M, Ahmed N, et al. Small molecule inhibitors as emerging cancer therapeutics. Integr Cancer Sci Ther. 2014;1(3):39–46.
   Google Scholar
• Scodeller PaA P, Asciutto EK. Targeting tumors using peptides. Molecules. 2020;25(4):808.
   Web of Science ®Google Scholar
• Fedele C, Singh A, Zerlanko BJ, et al. The αvβ6 integrin is transferred intercellularly via exosomes. J Biol Chem. 2015;290(8):4545–4551.
   PubMed Web of Science ®Google Scholar
• Lu H, Bowler N, Harshyne LA, et al. Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol. 2018;70:20–35.
   PubMed Web of Science ®Google Scholar